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optimization criteria for a certain patient regarding election between 
E or PH boost with similar CTV coverage. 
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Purpose/Objective: Head and neck cancer treatment is associated 
with significant morbidities. Both exclusive radiotherapy (RT) and 
chemoradiotherapy (CHRT) treatments can produce, as side effects, 
increased rates of long-term dysphagia. The purpose of the study here 
presented was to evaluate the ability of videofluoroscopy (VDF) in 
detecting and measuring swallowing dysfunction secondary to 
treatments. 
Materials and Methods: Eight head-and-neck cancer patients, who 
underwent radical RT till 70 Gy (5 fractions per week, 2 Gy per 
fraction), and concurrent chemotherapy (CHT) when indicated, were 
included. Treatment schedules administered to each patient (RT total 
dose, radiation fields, delivery techniques, CHT schemes) were 
decided according the NCCN recommendations. Half of patients 
received exclusive RT and the other half concomitant CHRT.  
In order to evaluate a possible swallowing dysfunction, VDF were 
performed before and after the treatment. Patients presenting 
swallowing dysfunction before the treatment were excluded. Post-
treatment evaluation was undertaken twice: early (1-3 months) and 
late post-therapy (4-9 months). The VDF explored swallowing 
dysfunction with the standard different textures. 
Results: Three patients developed some swallowing dysfunction in 
early post-therapy evaluation and, in the late post-therapy 
evaluation, 7 patients showed propulsive defect of the pharynx and 6 
of them had also residue. Only one patient had symptoms related to 
this dysfunction. No case of pneumonia by aspiration was reported. 
Conclusions: Swallowing dysfunction is a prevalent side effect after 
intensive RT and CHRT treatment in head-and-neck cancer patients. In 
our first 8 patients included, most frequent swallowing dysfunction 
was the propulsive defect of the pharynx asymptomatic in most of the 
cases. VDF was very effective in detecting, measuring and controlling 
this side effect. However, in order to confirm these results, inclusion 
of more patients is required. Therefore, patient enrolment continues. 
   
PO-0914   
Quantitative assessment of acute skin erythema and pigmentation 
due to breast radiation using spectrophotometry 
L. Lozza1, M.C. De Santis1, M. Carrara2, T. Rancati3, T. Giandini2, E. 
Pignoli2, N. Zaffaroni4, R. Valdagni5 
1Fondazione I.R.C.C.S Istituto Nazionale Tumori di Milano, 
Radiotherapy 1, Milan, Italy  
2Fondazione I.R.C.C.S Istituto Nazionale Tumori di Milano, Medical 
Physics, Milan, Italy  
3Fondazione I.R.C.C.S Istituto Nazionale Tumori di Milano, Prostate 
Cancer Program, Milan, Italy  
4Fondazione I.R.C.C.S Istituto Nazionale Tumori di Milano, 
Experimental Oncology and Molecular Medicine, Milan, Italy  
5Fondazione I.R.C.C.S Istituto Nazionale Tumori di Milano, Prostate 
Cancer Program and Radiotherapy 1, Milan, Italy  
 
Purpose/Objective: In daily clinical practice, acute adverse skin 
reactions due to radiation therapy (RT) are graded by the experienced 
eye of the radiation oncologist. However, such subjective grading 
provides only rough estimates of RT response. In addition, a great 
range of skin reactions is observed even between patients undergoing 
the same treatment. Aim of our study was to implement a 
quantitative method, based on reflectance spectrophotometry (RS), 
for objective in vivo measurements of skin erythema and pigmentation 
due to RT. Correlations between RS measurements and both clinicians' 
skin toxicity perceptions and delivered superficial doses were 
investigated. 
Materials and Methods: Patients treated with tangential fields to the 
breast parenchyma were included. RT prescribed dose: 50-60Gy, 2Gy 
per fraction. Skin RS measurements were obtained by means of a 
commercially available system (SpectroShade, MHT) which allows to 
acquire skin reflectance data between 483 and 950nm inside an useful 
field of view of 18x14mm2. Measurements were performed before RT 
and approximately every 6 (range 4-8) RT fractions up to the end of 
the RT treatment. At the same time, skin acute toxicity grade (ATG) 
reactions were visually assessed and recorded by the physician using 
RTOG scoring system.Both instrumental RS measurement and 
subjective ATG were performed at five different fixed points within 
the area treated with RT. RS relative changes at two selected band 
widths centred at 560nm (haemoglobin absorption peak) and720nm 
(mainly melanin absorption) were analysed and their correlation with 
ATG and delivered superficial dose was investigated. 
Results: Preliminary analysis of measurements at inframammary fold 
on 11 pts is here presented. SkinRS relative changes at 560nm 
(RSRC560nm) were a strong indicator of skin erythema and correlated 
well with clinical ATG evaluation (fig 1a). No evidence of a 
relationship between superficial absorbed doses (at inframammary 
fold) and RSRC560nm was obtained. However, after an initial 30Gy 
irradiation, where patient-to-patient variability to RT resulted to be 
extremely high, RSRC560nm data clearly indicate the existence of 3 
different groups of patients, i.e. over- normal- and under- reacting to 
RT, with RSRC560nm values <0.6 (3pts), in 0.8-0.9 range (6pts) and 
>1.1 (2pts), respectively (fig 1b). Finally, skin RS relative changes at 
720nm (RSRC720nm) resulted to be mostly related to skin 
pigmentation and started to slightly modify at the very end of the RT.  
  
Conclusions: RS is a good and objective tool to evaluate skin 
erythema and pigmentation changes. Although preliminary, these data 
are very interesting and do deserve further investigation. More 
patients will be recruited to investigate the origin of the variation in 
patients' radiosensitivity, at the genetic level. 
This study was funded by a grant of Mrs M. Bonatti and Mr G. Mameli 
and by the National Cancer League 
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Purpose/Objective: This study explores the relationship between the 
severity of late normal tissue damage in the irradiated breast, i.e. 
fibrosis leading to breast shrinkage, and the variation in residual DSBs, 
and in damage response markers (p21 and p53) of dermal fibroblasts 
isolated from skin biopsies of the patient and irradiated in-vivo or in-
vitro. 
Materials and Methods: 35 breast cancer patients with minimal 
(controls) or marked late fibrotic changes in the irradiated breast 
(cases) were selected 5 to 10 years after postoperative radiotherapy 
after breast preserving surgery. Skin biopsies of 4 mm diameter were 
taken 24 h or 12 weeks after irradiation of a field of 4 x 2 cm² in the 
lower back with 4 Gy using 6 MeV electrons. Punch biopsies were 
taken from both the irradiated and the contralateral unirradiated 
skin. Primary fibroblast cultures were established by outgrowth from 
those fresh irradiated and unirradiated skin biopsies which were 
collected 12 weeks after exposure. Residual DSBs were quantified in 
tissue sections from irradiated and unirradiated skin as well as in 
primary fibroblasts cultures which were irradiated in-vitro with 4 Gy 
as well by scoring 53BP1 foci. P53 and p21 levels were measured in 
fibroblast cultures. 
Results: 24 h after in-vitro irradiation the residual number of 53BP1 
foci increased compared to levels in unirradiated fibroblast cultures. 
The increase is larger in fibroblasts isolated from the cases than from 
the control patients. By contrast, the in-vivo irradiated samples which 
were established 12 weeks after irradiation have essentially the same 
number of foci as the unirradiated cells. The expression of p53 is 
